JAK2 and COVID-19: Among them, baricitinib, a pyrrolopyrimidine analog, is widely applied for treatment of severe COVID-19 in combination with remdesivir.319 Baricitinib is an oral selective inhibitor of JAK1 and JAK2.320 It was initially predicted by artificial intelligence algorithms as a potential treatment strategy against SARS-CoV-2.